Do you face challenges managing your HAE attacks?
Answer 5 questions to find out if your attack management journey compares to what others in the community have shared.
START
FOR UPDATES, RESOURCES, AND NEW PATIENT STORIES
Sign Up
We partnered with the HAE community to find out:
-
1How people living with HAE plan for an attack and make decisions about on-demand treatment
-
2How attacks impact quality of life
The results revealed that sometimes people delay on-demand treatment or don't treat attacks because of:
Difficulty carrying
their on-demand treatment wherever they go
Anxiety
of whether to treat when they recognize an attack
Fear of injection
or pain of medication
Lack of privacy
required to administer medication and a preference to treat at home
The HAE Attack Journey survey included 107 people living with HAE
-
54/107
treat with
prophylaxis
53/107
treat with
on-demand
only -
21 male and
86 female
participants -
56 people who were
<40 years old
and 51 who were
≥40 years old
Learn more about this survey
The HAE Attack Journey Survey was conducted by KalVista Pharmaceuticals in partnership with the HAE community to better understand how people living with HAE plan for an attack, make decisions about on-demand treatment, and how attacks impact their quality of life. This survey was based on the findings of an earlier pilot survey (N=32), which revealed that the majority of people living with HAE continue to experience a prolonged attack journey, despite advances in treatment.
The survey was conducted online from April to October 2022 and asked 107 members of the Hereditary Angioedema Association questions about HAE attacks and their current on-demand treatment experience.
THERE WERE 54 PEOPLE ON PROPHYLAXIS AND 53 TAKING ON-DEMAND ONLY
*For Firazyr, 44 people were on prophylaxis and on-demand, and 40 were taking on-demand only; for Ruconest, 3 people were on prophylaxis and on-demand, and 10 were taking on-demand only; for Berinert, 6 people were on prophylaxis and on-demand, and 3 were taking on-demand only; for Kalbitor, 1 person was on prophylaxis and on-demand, and 0 were taking on-demand only. Cinryze, Firazyr, Kalbitor, and Takhzyro are registered trademarks of Takeda or its affiliates. Berinert and Haegarda are registered trademarks of CSL Behring GmbH. Orladeyo is a registered trademark of BioCryst Pharmaceuticals, Inc. Ruconest is a registered trademark of Pharming Intellectual Property, B.V.
The HAE Attack Journey Survey showed that people living with HAE:
-
1Continue to have attacks even
if they’re taking prophylaxis -
2Go through a complex on-demand,
decision-making process that
results in delayed treatment -
3Have prolonged attacks and longer
recovery, resulting in significant
physical and psychological burden
CLOSE SURVEY DETAILS
Review the HAE Attack Journey Survey results
Attack preparation:
People living with HAE miss opportunities to treat attacks early
ATTACK RECOGNITION:
PEOPLE LIVING WITH HAE CAN CONSISTENTLY RECOGNIZE THE ONSET OF THEIR ATTACKS
Decision-making:
DESPITE RECOGNIZING THE
START OF AN HAE ATTACK, NEARLY ALL RESPONDENTS DELAY
ON-DEMAND TREATMENT
RESOLUTION:
DELAYING ON-DEMAND TREATMENT IMPACTED ATTACK SEVERITY AND RECOVERY TIME
Attack preparation
Attack recognition
Decision-making
Resolution
For the best experience, the HAE Attack Journey requires your device to be sideways. Please turn your device to continue.
START THE Experience
Do these results reflect your own experience?
Check out our resources to help you create an attack management plan that works for you.
See Resources
Back to top